Article Text

Download PDFPDF

AB0759 Neuropathic pain prevalence in psoriatic arthritis and its correlation with disease activity
  1. HE Öz1,
  2. S Tuna1,
  3. Ü Uçar Gürbüz2,
  4. N Balcı Vedin1
  1. 1Physical Therapy and Rehabilitation, Akdeniz University, Antalya
  2. 2Rheumatology, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey


Background Psoriatic arthritis (PsA) is a systemic chronic inflammatory disease associated with psoriasis. Neuropathic pain is defined as pain which is produced by a primary lesion or dysfunction of peripheral or central nervous system.

Objectives The aim of this study is to investigate the neuropathic pain component of chronic joint pain in psoriatic arthritis and to detect its correlation with disease activity and functional capacity.

Methods During the patients' routine outpatient clinic visit, we gain information about patients' demographics. We used Pain Detect questionnaire to detect neuropathic pain component, Visual Analogue Scale for joint pain, Disease Activity Score 28-Joint (DAS28) for disease activity evaluation and Health Assessment Questionnaire (HAQ) for functional capacity evaluation.

Results There were 48 PsA patients and 34 control patients in this study. Mean age was 52 (21–79), mean BMI is 27.5 kg/m2 (20.8–53) and mean disease duration was 5 year in PsA group. Mean age was 54 (20.8–53), mean BMI was 27.6 kg/m2 (20.8–53) in control group. Neuropathic pain component was positive in 22.9% of PsA and negative in 45.8% of PsA and unclear in 31.2% of PsA group. In control group, neuropathic pain component was positive in 35.3% of patients and negative in 41.2% of patients and unclear in 23.5% of patients. Mean pain detects score was 13 in PsA and 14 in control group. There was no statistically important difference between the PsA and control group's neuropathic pain prevalence (p=0.601) and mean PD score (p=0.24). Mean DAS 28 score was 3.5 (1–3.56) and mean HAQ score was 0.65 (0–2.05) in PsA group. There was a statistically important positive correlation between the PD score and HAQ score in PsA patients (Ro=0.460, p=0.001). In addition, there was a statistically unimportant positive correlation between the PD score and DAS28 score in PsA patients. There was a statistically unimportant positive correlation between the PD score and HAQ score in control group (Ro=0.411, p=0.016).

Conclusions We detected neuropathic pain component in 22.9% of PsA patients but there was no difference between the PsA group and control group. Diagnosis of concomitant neuropathic pain by Pain Detect Questionnaire may be useful for pain management in PsA patients.

Disclosure of Interest None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.